|
|
 Previous Article | Table of Contents | Next Article 
Telomerase activation in normal B lymphocytes and non-Hodgkin's lymphomas
KF Norrback, K Dahlenborg, R Carlsson and G Roos
Department of Pathology, Umea University Sweden.
Activation of telomerase seems to be a prerequisite for immortalization and
is found in permanent cell lines and most malignant tumors. Normal somatic
cells are generally telomerase negative, except for bone marrow stem cells.
Weak activity is also present in peripheral blood cells. In the present
study strong telomerase activity was demonstrated in vivo in normal mature
cells of the immune system, as well as in malignant lymphomas. Benign lymph
nodes had lower telomerase activity than benign tonsils, which exhibited
intermediate to high activity comparable with findings in malignant
lymphomas. In benign tonsils the activity seemed to be restricted to
germinal center B cells. In benign lymphoid tissues telomerase activity
correlated with B-cell numbers and cell proliferation, but this was not
observed in the lymphoma group. High- grade lymphomas exhibited higher
levels of telomerase compared with low- grade cases. The data showed that
in vivo activation of telomerase is a characteristic feature of germinal
center B cells. Different signals for activation of telomerase are likely
to exist, one of them being immune stimulation. The data suggest that
telomerase activity in malignant lymphomas can be explained by an
"induction and retention" model, ie, transformation occurs in a normal,
mature B cell with reactivated telomerase, which is retained in the
neoplastic clone.
Volume 88,
Issue 1,
pp. 222-229,
07/01/1996
Copyright © 1996 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H Veelken, S Vik Dannheim, J Schulte Moenting, U. Martens, J Finke, and A Schmitt-Graeff
Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy
Ann. Onc.,
May 1, 2007;
18(5):
931 - 939.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Grabowski, M. Hultdin, K. Karlsson, G. Tobin, A. Aleskog, U. Thunberg, A. Laurell, C. Sundstrom, R. Rosenquist, and G. Roos
Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status
Blood,
June 15, 2005;
105(12):
4807 - 4812.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. S. Wang, K. Wu, A. C. Chin, S. Chen-Kiang, K. Pongracz, S. Gryaznov, and M. A. S. Moore
Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma
Blood,
January 1, 2004;
103(1):
258 - 266.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.-D. Wu, L. M. Orme, J. Shaughnessy Jr, J. Jacobson, B. Barlogie, and M. A. S. Moore
Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival
Blood,
June 15, 2003;
101(12):
4982 - 4989.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. N. Prasad, A. R. Hovland, P. Nahreini, W. C. Cole, P. Hovland, B. Kumar, and K. C. Prasad
Differentiation Genes: Are They Primary Targets for Human Carcinogenesis?
Experimental Biology and Medicine,
October 1, 2001;
226(9):
805 - 813.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Lin, S. Lim, M. A. Viani, M. Sapp, and M. S. Lim
Down-Regulation of Telomerase Activity in Malignant Lymphomas by Radiation and Chemotherapeutic Agents
Am. J. Pathol.,
August 1, 2001;
159(2):
711 - 719.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. Hou, D. Xu, M. Bjorkholm, and A. Gruber
Real-Time Quantitative Telomeric Repeat Amplification Protocol Assay for the Detection of Telomerase Activity
Clin. Chem.,
March 1, 2001;
47(3):
519 - 524.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. H. Son, S. Murray, J. Yanovski, R. J. Hodes, and N.-p. Weng
Lineage-Specific Telomere Shortening and Unaltered Capacity for Telomerase Expression in Human T and B Lymphocytes with Age
J. Immunol.,
August 1, 2000;
165(3):
1191 - 1196.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K Y Lam, C Y Lo, S T Fan, and J M Luk
Telomerase activity in pancreatic endocrine tumours: a potential marker for malignancy
Mol. Pathol.,
June 1, 2000;
53(3):
133 - 136.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
W. Sun, K.-S. Kang, I. Morita, J. E. Trosko, and C.-C. Chang
High Susceptibility of a Human Breast Epithelial Cell Type with Stem Cell Characteristics to Telomerase Activation and Immortalization
Cancer Res.,
December 1, 1999;
59(24):
6118 - 6123.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Liu, M. M. Schoonmaker, B. L. Levine, C. H. June, R. J. Hodes, and N.-p. Weng
Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes
PNAS,
April 27, 1999;
96(9):
5147 - 5152.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.-F. Norrback, G. Enblad, M. Erlanson, C. Sundstrom, and G. Roos
Telomerase Activity in Hodgkin's Disease
Blood,
July 15, 1998;
92(2):
567 - 573.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. W. Greider
Telomerase activity, cell proliferation, and cancer
PNAS,
January 6, 1998;
95(1):
90 - 92.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N.-p. Weng, L. Granger, and R. J. Hodes
Telomere lengthening and telomerase activation during human B cell differentiation
PNAS,
September 30, 1997;
94(20):
10827 - 10832.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Engelhardt, R. Kumar, J. Albanell, R. Pettengell, W. Han, and M. A.S. Moore
Telomerase Regulation, Cell Cycle, and Telomere Stability in Primitive Hematopoietic Cells
Blood,
July 1, 1997;
90(1):
182 - 193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Brousset, T. Al Saati, N. Chaouche, R.-C. Zenou, D. Schlaifer, S. Chittal, and G. Delsol
Telomerase Activity in Reactive and Neoplastic Lymphoid Tissues: Infrequent Detection of Activity in Hodgkin's Disease
Blood,
January 1, 1997;
89(1):
26 - 31.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
